Cargando…
A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS
OBJECTIVE: To evaluate safety, dose response, and preliminary efficacy of reldesemtiv over 12 weeks in patients with amyotrophic lateral sclerosis (ALS). METHODS: Patients (≤2 years since diagnosis) with slow upright vital capacity (SVC) of ≥60% were randomized 1:1:1:1 to reldesemtiv 150, 300, or 45...
Ejemplares similares
-
Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study
por: Rudnicki, Stacy A., et al.
Publicado: (2021) -
Intermolecular And Dynamic Investigation of The Mechanism of Action of Reldesemtiv on Fast Skeletal Muscle Troponin Complex Toward the Treatment of Impaired Muscle Function
por: Issahaku, Abdul Rashid, et al.
Publicado: (2023) -
ALS drug development guidances and trial guidelines: Consensus and opportunities for alignment
por: Andrews, Jinsy A., et al.
Publicado: (2019) -
Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial
por: Paganoni, Sabrina, et al.
Publicado: (2022) -
Assessment of bulbar function in amyotrophic lateral sclerosis: validation of a self‐report scale (Center for Neurologic Study Bulbar Function Scale)
por: Smith, R. A., et al.
Publicado: (2018)